Achillion Pharmaceuticals (ACHN) Getting Somewhat Positive Press Coverage, Report Shows

Headlines about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Achillion Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.1917469360662 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern’s scoring:

Achillion Pharmaceuticals (ACHN) traded down 1.276% during trading on Wednesday, reaching $4.255. 355,195 shares of the company were exchanged. The firm’s 50-day moving average is $4.44 and its 200 day moving average is $4.26. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $7.34. The company’s market capitalization is $581.92 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). During the same quarter in the prior year, the business earned ($0.14) earnings per share. On average, analysts anticipate that Achillion Pharmaceuticals will post ($0.66) EPS for the current fiscal year.

ACHN has been the subject of several analyst reports. Maxim Group set a $7.00 target price on shares of Achillion Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Ladenburg Thalmann Financial Services dropped their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Finally, Robert W. Baird cut shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Thursday, August 10th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $6.75.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/18/achillion-pharmaceuticals-achn-getting-somewhat-positive-press-coverage-report-shows.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Insider Buying and Selling by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply